Trial Profile
Phase II Examination of Irinotecan, Cetuximab and Everolimus to Chemotherapy Resistent Patients With Metastatic Colorectal Cancer and KRAS Mutations or After Progression With KRAS Wildtype on Irinotecan and Cetuximab - Effect and Biological Markers.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Everolimus (Primary) ; Irinotecan (Primary)
- Indications Colorectal cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- Acronyms ICE
- 19 Mar 2012 Actual end date (Mar 2012) added as reported by ClinicalTrials.gov.
- 19 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 08 Jul 2011 New trial record